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Background: As part of the Affordable Care Act, a federal requirement for private health plans to cover contraceptive methods, services and
counseling, without any out-of-pocket costs to patients, took effect for millions of Americans in January 2013.
Study design: Data for this study come from a subset of the 3207 women aged 18–39 years who responded to two waves of a national
longitudinal survey. This analysis focused on the 889 women who were using hormonal contraceptive methods in both the fall 2012 and
spring 2013 waves and the 343 women who used the intrauterine device at either wave. Women were asked about the amount they paid out
of pocket in an average month for their method of choice.
Results: Between Wave 1 and Wave 2, the proportion of privately insured women paying zero dollars out of pocket for oral contraceptives
increased substantially, from 15% to 40%; by contrast, there was no significant change among publicly insured or uninsured women (whose
coverage was not affected by the new federal requirement). Similar changes were seen among privately insured women using the vaginal ring.
Conclusions: The initial implementation of the federal contraceptive coverage requirement appears to have had a notable impact on the out-of-
pocket costs paid by privately insured women. Additional progress is likely as the requirement phases in to apply to more private plans, but with
evidence that not all methods are being treated equally, policymakers should consider stepped-up oversight and enforcement of the provision.
Implications: This study measures the out-of-pocket costs for women with private, public and no insurance prior to the federal
contraceptive coverage requirement and after it took effect; in doing so, it highlights areas of progress in eliminating these costs and areas
that need further progress.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Contraception; Oral contraceptive pills; Insurance; Health care reform; Out-of-pocket costs1. Introduction
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Open access under CCfor women and that they do so without requiring copay-
ments, deductibles or other forms of out-of-pocket costs for
their enrollees [1]. This requirement — part of a broader
provision requiring coverage without cost sharing for dozens
of recommended preventive care services — was phased in
starting in August 2012.
Coverage of a wide range of contraceptive methods was
already standard in U.S. private health plans. According to
the most recent in-depth study of insurance coverage of
contraception, a nationally representative survey of private
U.S. health insurers in 2002, almost every reversible and
permanent contraceptive method available was covered by
89% or more of typical insurance plans at that time [2].
Moreover, at the time the federal requirement went into
effect in 2012, 28 states already had requirements in place BY-NC-ND license.
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prescription contraceptive methods [3].
Where the federal requirement broke new ground, at least
for private health plans, was in its prohibition on patient cost
sharing. That change brought with it the potential to eliminate
cost as a reason for choosing one method of contraception
over another, a change that could be particularly important
for women considering an intrauterine device (IUD) or
implant — methods that are highly effective and cost
effective but have substantial upfront costs. Federal law
since the early 1970s has similarly prohibited cost sharing for
contraceptive methods and services under Medicaid [4].
The new federal contraceptive coverage requirement is
not applicable to all health plans and enrollees. First, the
requirement is being phased in, affecting new plans as
they are created and existing plans when they begin a new
plan year; because most plans begin their plan year in
January, millions of enrollees gained these coverage
protections in January 2013. In addition, existing plans are
grandfathered— exempt from the requirement— so long as
they make no significant negative changes, such as benefit
reductions or cost-sharing increases; 36% of covered workers
were enrolled in a grandfathered health plan in 2013 [5].
Second, the federal government has granted an exemption
to the requirement for health plans offered by houses of
worship and other religious employers [6], and dozens of for-
profit and not-for-profit employers have challenged the
contraceptive coverage requirement in court, claiming it is a
violation of religious rights [7]. With federal appeals courts
already having issued conflicting rulings on the subject, the
U.S. Supreme Court will address the controversy during its
2014 spring session.
Moreover, it is not yet clear how the requirement is being
interpreted and implemented by health plans. The federal
government provided some guidance in a set of “frequently
asked questions” released in February 2013 [8]. Notably, that
guidance clarifies that plans must cover “the full range” of
contraceptive methods approved by the Food and Drug
Administration when prescribed for a woman, and specifi-
cally mentions the IUD and implant as examples. However,
the guidance repeated earlier assurances that health plans
may use “reasonable medical management techniques”; the
specific example given is that plans may use drug
formularies that require copayments for some brand-name
drugs that have generic equivalents. Plans must have a
process to waive such restrictions when a woman’s provider
determines that it is medically appropriate for her needs to do
so. The guidance also reaffirmed that the contraceptive
coverage requirement applies only to services obtained from
in-network providers, but it clarified that a plan must cover a
given service out of network without cost sharing if the
plan’s network does not have anyone to provide that service.
This article provides the first national-level data about the
initial reach and impact of the contraceptive coverage
requirement. It takes advantage of information collected
from a longitudinal survey of women, comparing women’sresponses in fall 2012 (before the contraceptive coverage
requirement would have taken effect for most women) and
spring 2013 (after the requirement would have come into
force for millions).2. Materials and methods
Data for this analysis come from Waves 1 and 2 of the
Guttmacher Institute’s Continuity and Change in Contra-
ceptive Use study, which is examining women’s contracep-
tive use over an 18-month time period. The study is being
administered online to a national sample of women aged 18–
39 years. We opted for online administration because it is the
most efficient way to collect information from large national
samples, as the changing dynamics of home and cell phone
use have made phone surveys less representative [9]. Recent
work has indicated that Internet surveys of probability-based
samples, along with post-stratification weights, can achieve
results that are comparable to or in some cases better than
telephone surveys [10–12].
We subcontracted with GfK (formerly Knowledge
Networks) to administer the survey using their Knowledge-
Panel, a national household panel recruited using a
probability-based methodology. The panel totals approxi-
mately 50,000 individual household members older than 13
years and is representative of the U.S. population. GfK uses
address-based sampling to recruit panel members; if a
household invited to participate in the panel lacks a computer
or Internet access, GfK provides them free of charge. GfK
estimates that its panel covers 97% of U.S. households. This
panel has been used previously in several published papers
on sexual behavior and contraception, demonstrating the
willingness of the sample members to participate in surveys
related to sexual behavior [13–16]. In particular, the
distribution of contraceptive users in the KnowledgePanel
has been found to be similar to that in the National Survey of
Family Growth, an in-home nationally representative survey
that is arguably the best source of information about
reproductive health behaviors in the United States [17].
In order to focus on women at risk of pregnancy, our
baseline survey population was restricted to women aged
18–39 years who had ever had vaginal sex with a man, who
were not currently pregnant, who had not had a tubal ligation
and whose main sexual partner had not had a vasectomy.
(Although women aged 40–44 or 40–49 years are often
considered to be within the fecund range, their fecundity is
typically lower than that of younger women. In addition,
they have lower rates of unintended pregnancy and
substantially higher rates of sterilization; the latter group
would have been ineligible to participate.)
The baseline (Wave 1) survey instrument contained
approximately 60 questions, and the median time for survey
completion was 12 min. Over a 3-week period in November
and December of 2012, 11,365 women between the ages 18
and 39 years were invited to participate in the survey. Of those,
Table 1
Percent of women who paid US$0 for their method, by method, insurance type and study wave
Only women who used the same method and had the same insurance type at both Wave 1 and Wave 2 (paired data and tests)
Method and
insurance type
N % who paid US$0 Difference Significance
Wave 1 Wave 2
Pill
Private 624 15 40 +25 ***
Public 71 65 79 +14 ns
None 65 28 34 +5 ns
Vaginal ring
Private 49 23 52 +29 **
Public 9 a a – –
None 4 a a – –
Injectable
Private 37 39 31 −8 ns
Public 20 a a – –
None 10 a a – –
Women who used the method at either Wave 1 or Wave 2 (unpaired data and tests)
Method and
insurance type
NW1 NW2 % who paid US$0 Difference Significance
Wave 1 Wave 2
IUD
Private 211 28 47 42 −5 ns
Public 50 8 92 a – –
None 36 10 72 a – –
Asterisks indicate statistical significance at *pb.05, **pb.01 and ***pb.001. ns, not significant.
a N too small to calculate percentage.
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rate of 59%; 4647 of those were eligible to participate, and
4643 completed the full survey. Wave 2 was fielded over a 3-
week time period in May and June of 2013. A total of 3207
women, or 69% of the baseline respondents, completed the
Wave 2 survey. Nine respondents were excluded from the final
dataset because they were deemed ineligible.
Respondents could choose whether to take the survey in
English or Spanish, and participants received US$10
remuneration for each wave completed. GfK obtains
informed consent from all individuals prior to including
them in its panel; we did not obtain any identifying
information from respondents (e.g., name, date of birth).
The project was approved by our organization’s federally
registered institutional review board.
In this analysis, we focused on questions about out-of-
pocket payments for contraception among women who used
hormonal methods or the IUD in the last 30 days. All of these
women, by definition, were not actively seeking to become
pregnant. The specific questions were:
1. “In an average month, approximately how much do
you, yourself, pay for a one-month supply of the [pill/
patch/ring]?”
2. “How much do you, yourself, have to pay each time
you get your Depo-Provera shot?”
3. “How much did you, yourself, have to pay when you
got your [IUD/implant]?”Women were also asked about their health insurance
coverage at each wave and were given the choices of private
insurance, Medicaid or other government-sponsored health
insurance (asked using state-specific program names; we
denote this group as “public”), some other type of health
insurance or no health insurance. The number of women who
indicated “some other type” was only 1% of respondents, so
we omitted this group. The focus of the paper is on privately
insured women. We also looked at women with public
insurance and uninsured women as comparison groups
because we would not have expected coverage for women in
those groups to be affected by the new policy.
We examined the percentage of women who reported
paying nothing, as well as the distribution of women by
amount paid. We chose categories for the latter based on
heaping in the data.
Women who reported that they used the pill, patch,
vaginal ring or injectable during the last 30 days were asked
the above questions at each wave. Thus, for each of these
methods, we performed paired t tests of the differences
between waves for women who used the method at both
waves and had the same insurance coverage at both waves
(n=889). IUD users, on the other hand, were only asked
about cost the first time they reported use of the method
because it was expected that they would only pay when first
obtaining the method. Thus, we performed unpaired t tests
comparing those who obtained the IUD before their Wave 1
survey to the group of (different) women who obtained it
Fig. 1. Amount paid out of pocket, women who were privately insured at both waves, by method and study wave.
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sons were omitted if at least one wave had fewer than 25
respondents. The number of users of the patch and implant
were too small to conduct these analyses, so those methods
were excluded from this analysis. Analyses were conducted
using Stata 13, and all used post-stratification sampling
weights provided by GfK.3. Results
Among women who reported using the pill at both waves
and having private health insurance at both waves, the
proportion who did not pay anything increased substantially
and significantly, from 15% to 40%, between Waves 1 and 2
(Table 1). A similar increase was seen for vaginal ring users
with private insurance, from 23% to 52%. There was no
significant change among privately insured injectable users
or IUD users.
As expected, the proportion of publicly insured and
uninsured pill users who paid US$0 did not change
significantly between the two waves; for Wave 2, 79% of
publicly insured women and 34% of uninsured women paid
US$0. There were too few publicly insured or uninsured
users of the ring or the injectable to report findings. For the
IUD, only the Wave 1 samples were large enough: 92% of
publicly insured IUD users and 72% of uninsured IUD users
paid US$0 out of pocket in Wave 1.
Fig. 1 is limited to privately insured users and shows the
proportion of users who paid various amounts for eachmethod. Among pill users and ring users, the increase in
women paying US$0 appears to have been drawn roughly
evenly from the higher cost-sharing categories; a χ2 test of
the remaining categories across waves was not significant.
There was a significant decline in the proportion of IUD
users who paid US$91 or more, from 30% to 5%. The
increase in the proportion of injectable users who paid US$91
or more, from 0% to 18%, was not significant.
Among women who were privately insured pill users at
both waves, the Wave 1 mean out-of-pocket payment was
US$15.18 and the median was US$10; the Wave 2 mean was
US$9.57 and the median was US$5 (not shown).3.1. Limitations
Our study is subject to some limitations. The number of
respondents using methods other than the pill and injectable
was low, and in the case of the patch and the implant, it was
too low to analyze here. We hope that our two additional
planned rounds of data collection will increase some of these
sample sizes sufficiently to enable analysis and to detect
subtler or more gradual changes in out-of-pocket payments.
Only 59% of women who were asked to participate in the
Wave 1 survey did so, and 31% of those did not complete the
Wave 2 survey. While our response rates were comparable to
those of other studies using online administration [10,14–16],
the samplemight be biased if our respondents differed from the
national population in ways that correlate with contraceptive
use. Despite these concerns, it is reassuring that the findings
here are extremely similar to prior published research: The
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for the pill in Wave 1 of our study are almost identical to the
mean (US$15.13) andmedian (US$10) out-of-pocket payment
from another nationally representative study [18] carried out
before the new federal policy took effect.4. Discussion
The findings of this study indicate that the federal
contraceptive coverage requirement is already having a
substantial impact in eliminating out-of-pocket costs among
privately insured women for at least some methods of
contraception — including oral contraceptives, the most
popular reversible method in the United States. Between
fall 2012 and spring 2013, the proportion of pill users
paying US$0 out of pocket increased from 15% to 40%,
and the proportion for ring users increased from 23% to
52%. That this progress has happened so rapidly — in just
the first several months that the requirement has been in
wide effect — is particularly noteworthy.
Further progress can be expected as more private health
plans become subject to the requirement. Notably, the
grandfathered status that is exempting some health plans is
designed to be a temporary measure to allow for a smoother
transition to new federal rules. The number of people
enrolled in grandfathered plans has been declining rapidly,
from 48% of covered workers in 2012 to 36% in 2013 [5].
Even if all plans do eventually lose grandfathered status, the
proportion of women paying US$0 will never reach 100%;
for example, some women will choose a brand-name drug
with a generic equivalent, in which case their insurer could
legally charge a copayment.
The study does, however, also provide some evidence—
the lack of apparent improvement in cost sharing for the
injectable and the IUD — that private health plans may not
be treating every method of contraception identically. This is
in line with anecdotal evidence, as reported in the media, that
some plans were placing certain methods on a non-$0 tier of
their formularies or taking other steps that appear contrary to
a simple reading of the federal requirement to cover “the full
range” of methods [19]. Future research, including analyses
from additional rounds of this longitudinal study, could
assess continuing progress and problems and may be helpful
to inform policymakers’ decision making about oversight
and enforcement of the provision.
This analysis also found potential troubling violations of
federal Medicaid law. For Wave 2, about one fifth of women
with public insurance reported paying some amount out of
pocket for the pill. The vast majority of those women are
likely enrolled in Medicaid and should be entirely exempt
from cost sharing for family planning services and supplies
under a law that has been in force for four decades. That
potential problem echoes findings from several earlier
studies in which substantial numbers of women enrolled in
Medicaid plans reported out-of-pocket costs for contracep-tion [18,20]. Some of the publicly insured women in our
study who paid out of pocket for contraception may be
enrolled in another public program that does not have
Medicaid’s cost-sharing protections, such as subsidized
coverage designed for individuals above the income
cutoffs for Medicaid. Nevertheless, this finding suggests
a need for federal and state policymakers to reexamine
how the cost-sharing protections for contraception under
Medicaid are being applied by state agencies and
Medicaid managed care plans.
Substantial proportions of uninsured women reported
paying nothing out of pocket for the pill and the IUD. These
findings likely reflect the subsidized care provided by
publicly supported health centers, such as health depart-
ments, Planned Parenthood clinics and community health
centers, to low-income clients.
The findings of this study bode well for the health and
well-being of women, couples and families. Government
bodies and private sector experts have long recognized
contraceptive services as a vital and effective component of
preventive and public health care, and an extensive body of
research shows that contraceptive use helps women avoid
unintended pregnancy and improve birth spacing, resulting
in substantial health, social and economic benefits [21–23].
The new federal requirement, in giving women coverage
without cost sharing of a wide range of contraceptive
choices, may help them overcome financial barriers to
choosing a contraceptive method they will be able to use
consistently and effectively.
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